Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal STI-9199 for Symptomatic COVID-19
NCT05372783Phase 2Withdrawn
- Sponsor
- Sorrento Therapeutics
- Start
- Apr 2023
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of STI-9199 in coronavirus disease 2019 (COVID-19), sponsored by Sorrento Therapeutics. Planned start Apr 2023; status: withdrawn.
02
Drugs
STI-9199
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05372783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05372783.